RT Journal Article
T1 A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.
A1 Terry, Kathryn L
A1 Schock, Helena
A1 Fortner, Renée T
A1 Hüsing, Anika
A1 Fichorova, Raina N
A1 Yamamoto, Hidemi S
A1 Vitonis, Allison F
A1 Johnson, Theron
A1 Overvad, Kim
A1 Tjønneland, Anne
A1 Boutron-Ruault, Marie-Christine
A1 Mesrine, Sylvie
A1 Severi, Gianluca
A1 Dossus, Laure
A1 Rinaldi, Sabina
A1 Boeing, Heiner
A1 Benetou, Vassiliki
A1 Lagiou, Pagona
A1 Trichopoulou, Antonia
A1 Krogh, Vittorio
A1 Kuhn, Elisabetta
A1 Panico, Salvatore
A1 Bueno-de-Mesquita, H Bas
A1 Onland-Moret, N Charlotte
A1 Peeters, Petra H
A1 Gram, Inger Torhild
A1 Weiderpass, Elisabete
A1 Duell, Eric J
A1 Sanchez-Perez, Maria-Jose
A1 Ardanaz, Eva
A1 Etxezarreta, Nerea
A1 Navarro, Carmen
A1 Idahl, Annika
A1 Lundin, Eva
A1 Jirström, Karin
A1 Manjer, Jonas
A1 Wareham, Nicholas J
A1 Khaw, Kay-Tee
A1 Byrne, Karl Smith
A1 Travis, Ruth C
A1 Gunter, Marc J
A1 Merritt, Melissa A
A1 Riboli, Elio
A1 Cramer, Daniel W
A1 Kaaks, Rudolf
AB About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in contrast to 90% for local disease. This has prompted search for early detection biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis are the best source of information to evaluate early detection biomarkers. Here we evaluate the most promising ovarian cancer screening biomarkers in prospectively collected samples from the European Prospective Investigation into Cancer and Nutrition study. We measured CA125, HE4, CA72.4, and CA15.3 in 810 invasive epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% specificity as well as area under the receiver operator curve (C-statistic) for each marker individually and in combination. In addition, we evaluated marker performance by stage at diagnosis and time between blood draw and diagnosis. We observed the best discrimination between cases and controls within 6 months of diagnosis for CA125 (C-statistic = 0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). Marker performance declined with longer time between blood draw and diagnosis and for earlier staged disease. However, assessment of discriminatory ability at early stage was limited by small numbers. Combinations of markers performed modestly, but significantly better than any single marker. CA125 remains the single best marker for the early detection of invasive epithelial ovarian cancer, but can be slightly improved by combining with other markers. Identifying novel markers for ovarian cancer will require studies including larger numbers of early-stage cases. Clin Cancer Res; 22(18); 4664-75. ©2016 AACRSee related commentary by Skates, p. 4542.
YR 2016
FD 2016-04-08
LK http://hdl.handle.net/10668/9979
UL http://hdl.handle.net/10668/9979
LA en
DS RISalud
RD Apr 10, 2025